DK1643997T3 - Flupirtin-præparat til behandling af neurodegenerative lidelser i synsapparatet og diabetes mellitus - Google Patents

Flupirtin-præparat til behandling af neurodegenerative lidelser i synsapparatet og diabetes mellitus

Info

Publication number
DK1643997T3
DK1643997T3 DK04740166.6T DK04740166T DK1643997T3 DK 1643997 T3 DK1643997 T3 DK 1643997T3 DK 04740166 T DK04740166 T DK 04740166T DK 1643997 T3 DK1643997 T3 DK 1643997T3
Authority
DK
Denmark
Prior art keywords
flupirtine
preparation
diabetes mellitus
treatment
visual apparatus
Prior art date
Application number
DK04740166.6T
Other languages
English (en)
Inventor
Karl-Georg Schmidt
Original Assignee
Karl-Georg Schmidt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Karl-Georg Schmidt filed Critical Karl-Georg Schmidt
Application granted granted Critical
Publication of DK1643997T3 publication Critical patent/DK1643997T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK04740166.6T 2003-06-23 2004-06-22 Flupirtin-præparat til behandling af neurodegenerative lidelser i synsapparatet og diabetes mellitus DK1643997T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10328260A DE10328260A1 (de) 2003-06-23 2003-06-23 Flupirtine-Präparat
PCT/EP2004/006738 WO2005000306A1 (de) 2003-06-23 2004-06-22 Flupirtine-präparat zur behandlung von neurodegenerativen erkrankungen des sehapparates und von diabetes mellitus

Publications (1)

Publication Number Publication Date
DK1643997T3 true DK1643997T3 (da) 2011-02-28

Family

ID=33546620

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04740166.6T DK1643997T3 (da) 2003-06-23 2004-06-22 Flupirtin-præparat til behandling af neurodegenerative lidelser i synsapparatet og diabetes mellitus

Country Status (14)

Country Link
US (1) US20060205793A1 (da)
EP (1) EP1643997B1 (da)
JP (1) JP4921165B2 (da)
CN (2) CN1838955A (da)
AT (1) ATE487513T1 (da)
CY (1) CY1111608T1 (da)
DE (2) DE10328260A1 (da)
DK (1) DK1643997T3 (da)
ES (1) ES2356244T3 (da)
PL (1) PL1643997T3 (da)
PT (1) PT1643997E (da)
SI (1) SI1643997T1 (da)
WO (1) WO2005000306A1 (da)
ZA (1) ZA200600472B (da)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005054610B4 (de) * 2005-11-08 2010-06-10 Awd.Pharma Gmbh & Co. Kg Flupirtin enthaltende Arzneimittelzubereitung mit kontrollierter Wirkstofffreisetzung
CN102836156A (zh) * 2012-09-03 2012-12-26 天津红日药业股份有限公司 一种含马来酸氟吡汀的胶囊及其制备方法
CN104083335B (zh) * 2013-07-31 2015-11-11 成都苑东药业有限公司 一种马来酸氟吡汀胶囊组合物及其制备方法
CN107412186A (zh) * 2017-08-02 2017-12-01 瑞阳制药有限公司 含马来酸氟吡汀的组合物及其制备方法
CN109806243B (zh) * 2017-11-20 2022-07-15 北京泰德制药股份有限公司 一种含有氟吡汀或其药用盐的皮肤外用贴剂

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1A (en) * 1836-07-13 John Ruggles Locomotive steam-engine for rail and other roads
EP0189788B1 (de) * 1985-01-23 1989-09-13 ASTA Pharma Aktiengesellschaft Synergistische Kombination von Flupirtin und nicht-steroidalen Antiphlogistika
GB8625941D0 (en) * 1986-10-30 1986-12-03 Sandoz Ltd Substituted alpha-amino acids
IT1256022B (it) * 1992-06-08 1995-11-20 Preparazioni farmaceutiche stabili di nicorandil
DE4319649A1 (de) * 1993-03-18 1994-09-22 Asta Medica Ag Feste Flupirtin enthaltende orale Darreichungsformen mit kontrollierter Wirkstoffabgabe
DE4327516A1 (de) * 1993-08-17 1995-02-23 Asta Medica Ag Primäre und sekundäre neuroprotektive Wirkung bei neurodegenerativen Erkrankungen von Flupirtin
DE19625582A1 (de) * 1996-06-27 1998-01-02 Asta Medica Ag Verwendung von Flupirtin zur Prophylaxe und Therapie von Erkrankungen die mit einer unphysiologisch hohen Zellsterberate einhergehen
JP4372905B2 (ja) * 1999-09-02 2009-11-25 興和株式会社 網膜神経細胞保護剤
ZA200108038B (en) * 2000-10-02 2003-04-01 Pfizer Prod Inc Prophylactic use of n-methyl-d-asparrate (NMDA) antagonists.

Also Published As

Publication number Publication date
CY1111608T1 (el) 2015-10-07
DE502004011874D1 (de) 2010-12-23
US20060205793A1 (en) 2006-09-14
PL1643997T3 (pl) 2011-05-31
ES2356244T3 (es) 2011-04-06
EP1643997B1 (de) 2010-11-10
ZA200600472B (en) 2007-05-30
DE10328260A1 (de) 2005-01-27
EP1643997A1 (de) 2006-04-12
ATE487513T1 (de) 2010-11-15
CN102940633A (zh) 2013-02-27
CN1838955A (zh) 2006-09-27
JP4921165B2 (ja) 2012-04-25
WO2005000306A1 (de) 2005-01-06
JP2008529961A (ja) 2008-08-07
PT1643997E (pt) 2011-02-16
SI1643997T1 (sl) 2011-04-29

Similar Documents

Publication Publication Date Title
NO20074999L (no) Metode og preparat for behandling av perifere vaskulaere sykdommer
DE502005008790D1 (de) Substituierte phenylaminopyrimidine
NO20064186L (no) Substituerte pyrazolin sammensetninger for a redusere triglycerider i blod
GB0222495D0 (en) Compounds
MY148108A (en) Medicaments for the treatment or prevention of fibrotic diseases
DK1448564T3 (da) Substituerede indolizinlignende forbindelser og fremgangsmåder til anvendelse
NO20064041L (no) Substituerte pyrazolin sammensetninger, deres fremstilling og anvendelse som medikamenter
DE502005006149D1 (de) Hetaryloxy-substituierte phenylaminopyrimidine als rho-kinasehemmer
CY1108932T1 (el) Ενωσεις 4-(ετεροκυκλυλ)-βενζολοσουλφοξιμινης για την θεραπευτικη αγωγη φλεγμονωδων ασθενειων
UA107578C2 (uk) Комбінована терапія при лікуванні діабету
WO2006072589A3 (en) Disubstituted ureas as kinase inhibitors
NO20073830L (no) Medikamenter for behandling eller forebygging av fibrotiske sykdommer
GB0620385D0 (en) Novel compounds
WO2006035157A3 (fr) Composes derives de n- (benzyl) phenylacetamide substitues , preparation et utilisations comme ligands des ppar dans le traitement des dereglements lipidiques et/ou glucidiques
CY1111608T1 (el) Σκευασμα φλουπιρτινης για τη θεραπεια νευροεκφυλιστικων νοσων του οπτικου συστηματος και του σακχαρωδη διαβητη
TW200635595A (en) Medicaments for the treatment of prevention of fibrotic diseases
NO20082986L (no) Nye, acylisk substituerte furopyrimidinderivater og anvendelse derav for behandling av kardiovaskulaere lidelser
DK1784173T3 (da) Farmaceutisk sammensætning til forebyggelse og behandling af metaboliske knoglesygdomme indeholdende alpha-arylmethoxyacrylatderivater
CY1110369T1 (el) Νεος συνεργιστικος συνδυασμος ο οποιος περιεχει ροφλουμιλαστη και φορμοτερολη
MX2023000303A (es) Coagonistas de los receptores del peptido 1 similar al glucagon (glp-1) y del polipeptido insulinotropico dependiente de glucosa (gip) adecuados para el suministro oral.
WO2018005801A3 (en) Novel non-systemic tgr5 agonists
DK1610787T3 (da) Synergistisk kombination der omfatter roflumilast og et antikolinergt middel der er valgt blandt tiotropiumsalte til behandling af respiratoriske sygdomme
WO2009003694A3 (en) Method for treating diseases related to mitochondrial dysfunction
WO2008043788A3 (en) Novel compounds
NO20075199L (no) Treatment or prevention of pruritus